Browse
Submit Data
Databases
API
Help

Dataset Information

10 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Quarter Century of Anti-HIV CAR T Cells.

ABSTRACT: PURPOSE OF REVIEW:A therapy that might cure HIV is a very important goal for the 30-40 million people living with HIV. Chimeric antigen receptor T cells have recently had remarkable success against certain leukemias, and there are reasons to believe they could be successful for HIV. This manuscript summarizes the published research on HIV CAR T cells and reviews the current anti-HIV chimeric antigen receptor strategies. RECENT FINDINGS:Research on anti-HIV chimeric antigen receptor T cells has been going on for at least the last 25 years. First- and second-generation anti-HIV chimeric antigen receptors have been developed. First-generation anti-HIV chimeric antigen receptors were studied in clinical trials more than 15 years ago, but did not have meaningful clinical efficacy. There are some reasons to be optimistic about second-generation anti-HIV chimeric antigen receptor T cells, but they have not yet been tested in vivo.

SUBMITTER: Wagner TA

PROVIDER: S-EPMC5884727 | biostudies-literature | 2018 Apr

REPOSITORIES: biostudies-literature

ACCESS DATA

Json Xml

Publications

Quarter Century of Anti-HIV CAR T Cells.

Wagner Thor A TA

Current HIV/AIDS reports 20180401 2

<h4>Purpose of review</h4>A therapy that might cure HIV is a very important goal for the 30-40 million people living with HIV. Chimeric antigen receptor T cells have recently had remarkable success against certain leukemias, and there are reasons to believe they could be successful for HIV. This manuscript summarizes the published research on HIV CAR T cells and reviews the current anti-HIV chimeric antigen receptor strategies.<h4>Recent findings</h4>Research on anti-HIV chimeric antigen recepto ...[more]

PMID: 29500712

Similar Datasets

A quarter century of granzymes.

Project description:Granzymes (Grs) were discovered just over a quarter century ago. They are produced by cytotoxic T cells and natural killer cells and are released upon interaction with target cells. Intensive biochemical, genetic, and biological studies have been performed in order to study their roles in immunity and inflammation. This review summarizes research on the family of Grs.

| S-EPMC3252830 | biostudies-other

The Hopelessness Theory of Depression: A Quarter Century in Review.

Project description:Since the formulation of the hopelessness theory of depression (Abramson, Metalsky, & Alloy, 1989) a quarter century ago, it has garnered considerable interest. The current paper presents a systematic review of this theory including its subsequent elaborations (Rose and Abramson's [1992] developmental elaboration, Abela and Sarin's [2002] weakest-link approach, Panzarella, Alloy, and Whitehouse's [2006] expansion of the hopelessness theory, and the hopelessness theory of suicide [Abramson et al., 2000]), followed by recommendations for future study. Although empirical support was consistently found for several major components of the hopelessness theory, further work is required assessing this theory in relation to clinically significant phenomena. Among the most significant hindrances to advancement in this area is the frequent conceptual confusion between the hopelessness theory and the reformulated learned helplessness theory.

| S-EPMC4689589 | biostudies-literature

Pertussis in high-risk groups: an overview of the past quarter-century.

Project description:Infectious diseases can impact chronic medical conditions. However, it is currently not clear how pertussis correlates with preexisting or underlying disorders. We reviewed literature from the last 25 years to describe the burden and impact of pertussis infection in specific risk groups in individuals aged ≥11 years. Our literature search returned 543 hits, of which 18 were eligible for this review. Adolescents and adults with underlying conditions, such as asthma, chronic obstructive pulmonary disease (COPD), or obesity are potentially at increased risk of pertussis infection. Immunodeficiency and smoking have also been associated with worsened pertussis symptoms and an increased pertussis-related hospitalization rate. In patients with pertussis and preexisting asthma or COPD, symptoms were worsened, and health-care costs were consequently increased. Further efforts are needed to close the knowledge gap and to understand the burden of pertussis in at-risk adolescent and adult populations to help inform vaccination strategies and recommendations.

| S-EPMC7746252 | biostudies-literature

Inner workings: Hubble's quarter century in orbit has opened a universe of possibilities.

Project description: Not available

| S-EPMC4371921 | biostudies-literature

Anti-CAR-engineered T cells for epitope-based elimination of autologous CAR T cells.

Project description:Although CAR T-cell therapy has demonstrated tremendous clinical efficacy especially in hematological malignancies, severe treatment-associated toxicities still compromise the widespread application of this innovative technology. Therefore, developing novel approaches to abrogate CAR T-cell-mediated side effects is of great relevance. Several promising strategies pursue the selective antibody-based depletion of adoptively transferred T cells via elimination markers. However, given the limited half-life and tissue penetration, dependence on the patients' immune system and on-target/off-side effects of proposed monoclonal antibodies, we sought to exploit αCAR-engineered T cells to efficiently eliminate CAR T cells. For comprehensive and specific recognition, a small peptide epitope (E-tag) was incorporated into the extracellular spacer region of CAR constructs. We provide first proof-of-concept for targeting this epitope by αE-tag CAR T cells, allowing an effective killing of autologous E-tagged CAR T cells both in vitro and in vivo whilst sparing cells lacking the E-tag. In addition to CAR T-cell cytotoxicity, the αE-tag-specific T cells can be empowered with cancer-fighting ability in case of relapse, hence, have versatile utility. Our proposed methodology can most probably be implemented in CAR T-cell therapies regardless of the targeted tumor antigen aiding in improving overall safety and survival control of highly potent gene-modified cells.

| S-EPMC6768917 | biostudies-literature

Social change and cohort differences in group-based arrest trajectories over the last quarter-century.

Project description:This article draws on official criminal histories for multiple birth cohorts spanning a 17-y difference in birth year to study how social change can alter our understanding of influential theories and policies about criminal offender groups. Arrest histories are linked to comprehensive longitudinal measurement on over 1,000 individuals originally from Chicago. Using group-based trajectory modeling, we investigated the magnitude and type of cohort differences in trajectories of arrest over the period 1995 to 2020. Our results show that trajectory group membership varies strongly by birth cohort. Membership in the nonoffender group is nearly 15 percentage points higher for cohorts born in the mid-1990s as compared to those born in the 1980s; conversely, older cohorts are more likely to be members of adolescent-limited and chronic-offender groups. Large cohort differences in trajectory group membership persist after controlling for a wide-ranging set of demographic characteristics and early-life risk factors that vary by cohort and that prior research has identified as important influences on crime. Not only does the effect of social change on cohort differentiation persist, but its magnitude is comparable to-indeed larger than-differences in trajectory group membership associated with varying levels of self-control or by whether individuals grew up in high-poverty households. These results suggest that changes in the broader social environment shared by members of the same birth cohort are as powerful in shaping their trajectory group membership as classic predictors identified in prior research, a finding that carries implications for crime-control policies that rely on prediction.

| S-EPMC8346896 | biostudies-literature

A Quarter Century of APOE and Alzheimer's Disease: Progress to Date and the Path Forward.

Project description:Alzheimer's disease (AD) is considered a polygenic disorder. This view is clouded, however, by lingering uncertainty over how to treat the quasi "monogenic" role of apolipoprotein E (APOE). The APOE4 allele is not only the strongest genetic risk factor for AD, it also affects risk for cardiovascular disease, stroke, and other neurodegenerative disorders. This review, based mostly on data from human studies, ranges across a variety of APOE-related pathologies, touching on evolutionary genetics and risk mitigation by ethnicity and sex. The authors also address one of the most fundamental question pertaining to APOE4 and AD: does APOE4 increase AD risk via a loss or gain of function? The answer will be of the utmost importance in guiding future research in AD.

| S-EPMC6407643 | biostudies-literature

CAR Talk: How Cancer-Specific CAR T Cells Can Instruct How to Build CAR T Cells to Cure HIV.

Project description:Re-directing T cells via chimeric antigen receptors (CARs) was first tested in HIV-infected individuals with limited success, but these pioneering studies laid the groundwork for the clinically successful CD19 CARs that were recently FDA approved. Now there is great interest in revisiting the concept of using CAR-expressing T cells as part of a strategy to cure HIV. Many lessons have been learned on how to best engineer T cells to cure cancer, but not all of these lessons apply when developing CARs to treat and cure HIV. This mini review will focus on how early CAR T cell studies in HIV paved the way for cancer CAR T cell therapy and how progress in cancer CAR therapy has and will continue to be instructive for the development of HIV CAR T cell therapy. Additionally, the unique challenges that must be overcome to develop a successful HIV CAR T cell therapy will be highlighted.

| S-EPMC6776630 | biostudies-literature

HIV-1-Specific CAR-T Cells With Cell-Intrinsic PD-1 Checkpoint Blockade Enhance Anti-HIV Efficacy <i>in vivo</i>.

Project description:Adoptive cellular immunotherapy therapy using broadly neutralizing antibody-based chimeric antigen receptor-T cells (bNAb-based CAR-T) has shown great potency and safety for the functional cure of HIV. The efficacy of bNAb-based CAR-T cells could be compromised by adaptive resistance during HIV chronic infection according to the phenomenon that cellular exhaustion was observed in endogenous cytotoxic T-lymphocytes (CTLs) along with upregulated expression of PD-1. Here, we created HIV-specific CAR-T cells using human peripheral blood mononuclear cells (PBMCs) and a 3BNC117-DNR CAR (3BD CAR) construct that enables the expression of PD-1 dominant negative receptor (DNR) and the single-chain variable fragment of the HIV-1-specific broadly neutralizing antibody 3BNC117 to target native HIV envelope glycoprotein (Env). Compared with HIV CAR expression alone, 3BD CAR-T cells displayed potent lytic and functional responses to Env-expressing cell lines and HIV-infected CD4+ T cells. Moreover, 3BD CAR-T cells can kill HIV-latently-infected cell lines, which are reactivated by the secretory cytokines of effector cells followed by contact with initial HIV-expressing fraction. Furthermore, bioluminescence imaging indicated that 3BD CAR-T cells displayed superior anti-HIV function in an HIV NCG mouse model of transplanting Env+/PD-L1+ cells (LEL6). These studies suggested that our proposed combinational strategy of HIV CAR-T therapy with PD-1 blockade therapy is feasible and potent, making it a promising therapeutic candidate for HIV functional cure.

| S-EPMC8290485 | biostudies-literature

TGF-?-responsive CAR-T cells promote anti-tumor immune function.

Project description:A chimeric antigen receptor (CAR) that responds to transforming growth factor beta (TGF-?) enables the engineering of T cells that convert this immunosuppressive cytokine into a potent T-cell stimulant. However, clinical translation of TGF-? CAR-T cells for cancer therapy requires the ability to productively combine TGF-? responsiveness with tumor-targeting specificity. Furthermore, the potential concern that contaminating, TGF-??producing regulatory T (Treg) cells may preferentially expand during TGF-? CAR-T cell manufacturing and suppress effector T (Teff) cells demands careful evaluation. Here, we demonstrate that TGF-? CAR-T cells significantly improve the anti-tumor efficacy of neighboring cytotoxic T cells. Furthermore, the introduction of TGF-? CARs into mixed T-cell populations does not result in the preferential expansion of Treg cells, nor do TGF-? CAR-Treg cells cause CAR-mediated suppression of Teff cells. These results support the utility of incorporating TGF-? CARs in the development of adoptive T-cell therapy for cancer.

| S-EPMC6063867 | biostudies-other

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data